Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
doi: https://doi.org/10.1101/2021.01.05.21249310
Ravikirti
1Department of General Medicine, All India Institute of Medical Sciences (AIIMS), Patna, India
Roles: Additional Professor and Head
Ranjini Roy
2Department of General Medicine, AIIMS, Patna, India
Roles: Postgraduate Trainee
Chandrima Pattadar
2Department of General Medicine, AIIMS, Patna, India
Roles: Postgraduate Trainee
Rishav Raj
3Department of General Medicine, AIIMS, Patna
Roles: Postgraduate Trainee
Neeraj Agarwal
4Department of Community and Family Medicine, AIIMS, Bibi Nagar, India
Roles: Professor and Head
Bijit Biswas
5Department of Community and Family Medicine, AIIMS, Patna, India
Roles: Senior Resident
Pramod Kumar Majhi
6Department of Pharmacology, AIIMS, Patna, India
Roles: Assistant Professor and Head
Deependra Kumar Rai
7Department of Pulmonary Medicine, AIIMS, Patna, India
Roles: Additional Professor and Head
Shyama
3Department of General Medicine, AIIMS, Patna
Roles: Assistant Professor
Anjani Kumar
3Department of General Medicine, AIIMS, Patna
Roles: Assistant Professor
Asim Sarfaraz
9Department of Microbiology, AIIMS, Patna
Roles: Assistant Professor
Data Availability
The data can be made available by the corresponding author on rasonable request.
Posted January 09, 2021.
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
medRxiv 2021.01.05.21249310; doi: https://doi.org/10.1101/2021.01.05.21249310
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
medRxiv 2021.01.05.21249310; doi: https://doi.org/10.1101/2021.01.05.21249310
Subject Area
Subject Areas
- Addiction Medicine (313)
- Allergy and Immunology (616)
- Anesthesia (158)
- Cardiovascular Medicine (2257)
- Dermatology (201)
- Emergency Medicine (368)
- Epidemiology (11550)
- Forensic Medicine (10)
- Gastroenterology (676)
- Genetic and Genomic Medicine (3542)
- Geriatric Medicine (336)
- Health Economics (612)
- Health Informatics (2287)
- Health Policy (910)
- Hematology (333)
- HIV/AIDS (742)
- Medical Education (357)
- Medical Ethics (100)
- Nephrology (386)
- Neurology (3327)
- Nursing (190)
- Nutrition (504)
- Oncology (1748)
- Ophthalmology (523)
- Orthopedics (208)
- Otolaryngology (283)
- Pain Medicine (222)
- Palliative Medicine (66)
- Pathology (436)
- Pediatrics (998)
- Primary Care Research (399)
- Public and Global Health (5975)
- Radiology and Imaging (1216)
- Respiratory Medicine (807)
- Rheumatology (367)
- Sports Medicine (311)
- Surgery (383)
- Toxicology (50)
- Transplantation (170)
- Urology (142)